Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-10-11
2005-10-11
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254020, C544S133000, C544S369000
Reexamination Certificate
active
06953796
ABSTRACT:
The present invention relates to the use of 2-amino-thiazoline derivatives of formula (I):in which either Y is a methylene (CH2) and X is chosen from the following groups: O, NH, (C1-C4) N-Alkyl, N—Bn, N—Ph, N-(2-Py), N-(3-Py), N-(4-Py), N-2-pyrimidyl, N-5-pyrimidyl, S, SO, SO2, CH2or CHPh; or Y is a carbonyl (C═O) and X is chosen from the following groups: NH, N—Ph, N-(2-Py), N-(3-Py), N-(4-Py), N-2-pyrimidyl or N-5-pyrimidyl or pharmaceutically acceptable salts thereof as inhibitors of inducible NO-synthase.
REFERENCES:
patent: 6420566 (2002-07-01), Carry et al.
patent: 6451821 (2002-09-01), Carry et al.
patent: 6699867 (2004-03-01), Bigot et al.
patent: 2003/0225140 (2003-12-01), Bacque et al.
patent: 2004/0192745 (2004-09-01), Ehrenreich et al.
patent: WO 94/12165 (1994-06-01), None
patent: WO 95/11231 (1995-04-01), None
patent: WO 96/14842 (1996-05-01), None
Lala, P.K. and Orucevic, A., “Role of nitric oxide in tumor progression: Lessons from experimental tumors,” Cancer and Metastasis Reviews (1998), 17(1):91-106.
Cummings, Jeffrey L., “Alzheimer's Disease,” N. Engl. J. Med. 351:56-67 (Jul. 1, 2004) at pp. 56-60.
Bullock, Roger, “Future directions in the treatment of Alzheimer's disease,” Expert Opin. Invest. Drugs 13(4): 303-314 (2004) at pp. 303, 306-309.
Robinson, Stephen R., et al., “Lessons from the AN 1792 Alzheimer vaccine: lest we forget,” Neurobiol. of Aging 25(5): 609-615 (May-Jun. 2004) at pp. 609-610.
Lacomblez, L. et al., “Dose-ranging study of riluzole in amyotrophic lateral sclerosis,” The Lancet, vol. 347(9013), pp. 1425-1431 (May 25, 1996), at p. 1429, col. 2, lines 25-26.
Keita, H., et al., “Anesthetic concentrations of riluzole inhibit neuronal nitric oxide synthase activity, but not expression, in the rat hippocampus,” Brain Research, vol. 881(2), pp. 237-240 (Oct. 2000), at p. 240, col. 1, lines 6-9 and 15-17.
Gilgun-Sherki, Y., et al., “Riluzole suppresses experimental autoimmune encephalomyelitis; implications for the treatment of multiple sclerosis,” Brain Research, vol. 989(2), pp. 196-204 (Nov. 2003), at p. 197, col. 1, lines 7-12; and p. 202, lines 27-30.
Chabrier, P., et al., “Nitric oxide synthases: targets for therapeutic strategies in neurological diseases,” Cell. Mol. Life Sci., vol. 55, pp. 1029-1035 (Sep. 1999), at p. 1029, col. 1, lines 10-18; p. 1030, col. 2, lines 7-48; p. 1032, lines 8-40, Table1.
Lassen, L., et al., “Nitric oxide synthase inhibition in migraine,” The Lancet, vol. 349, pp. 401-402 (Feb. 8, 1997), at p. 402, lines 2-5.
Stanislaus, R., et al., “Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin,” Neuroscience Letters, vol. 269, pp. 71-74 (Jul. 1999), at p. 73, col. 2, lines 3-8 and 31-32; and p. 74, col. 1, lines 5-15.
Bagasra, O., et al., “Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis,” Proc. Natl. Acad. Sci., vol. 92, pp. 12041-12045 (Dec. 1995), at p. 12045, col. 1, lines 1-4.
Lee, T.J.F., “Nitric Oxide and the Cerebral Vascular Function,” J. Biomed. Sci., vol. 7(1), pp. 16-26 (Jan.-Feb. 2000), at p. 23, col. 2, lines 16-17; p. 24, lines 23-35 et seq.
Masukawa, T., et al., “Role of Nitric Oxide in the Convulsions Following the Coadministration of Enoxacin with Fenbufen in Mice,” Jpn. J. Pharmacol., vol. 76(4), pp. 425-429 (Apr. 1998), at p. 428, col. 1, lines 2-12.
Pozza, M., et al., “Further evidence for a role of nitric oxide in experimental allergic encephalomyelitis: aminoguanidine treatment modifies its clinical evolution,” Brain Research, vol. 855(1), pp. 39-46 (Feb. 2000), at p. 39, col. 2, lines 5-23.
Giovannoni, G., et al., “The potential role of nitric oxide in multiple sclerosis,” Multiple Sclerosis, vol. 4(3), pp. 212-216 (Jun. 1998), at p. 213, col. 2, lines 37-62 and p. 214, col. 1, lines 8-13.
Miljkovic, D., et al., “Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes,” Brain Research, vol. 889(1-2), pp. 331-338 (Jan. 2001), at p. 331, col. 2, lines 5-14; p. 337, col. 2, lines 1-3.
Torreilles, F., et al., “Neurodegenerative disorders: the role of peroxynitrite,” Brain Research Reviews, vol. 30(2), pp. 153-163 (Aug. 1999), at p. 154, col. 1, lines 5-10 and 21-29; p. 158, col. 2, lines 14-40 et seq.
Milos Hudlicky, Oxidations In Organic Chemistry, American Chemical Society (1990, pp. 252-263, vol. 186).
Salvador Moncada et al., Bioynthesis Of Nitric Oxide From L-Arginine A Pathway For The Regulation Of Cell Function And Communication, Biochemical Pharmacology, (1989, pp. 1709-1715, vol. 38, No. 11).
Bigot Antony
Carry Jean-Christophe
Mignani Serge
Aventis Pharma S.A.
Newman Irving
Paviglianiti Anthony J
Saeed Kamal A.
LandOfFree
Use of 2-amino-thiazoline derivatives as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 2-amino-thiazoline derivatives as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 2-amino-thiazoline derivatives as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3490647